<DOC>
	<DOCNO>NCT02047487</DOCNO>
	<brief_summary>This randomize , open control multicenter phase II clinical study . The SPSS statistical software estimation sample size , selection initial treatment locally advanced head neck squamous cell carcinoma 120 patient , achieve desire result , consider expand clinical , accord proportion 1:1 randomly divide two group , patient take , docetaxel + cisplatin 2 cycle induction chemotherapy 、Concurrent chemoradiotherapy（tomotherapy+cisplatin） , The experimental group add AVASTIN .</brief_summary>
	<brief_title>After Induction Chemotherapy DP Plus DDP Concurrent Radiotherapy With Without Bevacizumab Study</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Men woman limit , requirement ECOG02 , age 1870 year old , pathological stage III ( NCCN2012 ) , receive radiotherapy chemotherapy , expect survive 3 month , routine testing , normal range , sign inform consent Do meet criterion ; allergic docetaxel AVASTIN , metabolic disorder ; associate gastrointestinal bleeding , perforation serious disease ; severe liver disease , kidney disease , respiratory disease unable control diabetes , hypertension chronic disease ; heart disease clinical symptom ; peripheral nervous system disorder obvious mental disorder disorder central nervous system ; active phase &gt; CTCAE2 clinical severe infection ; history organ transplantation ( include bone marrow transplantation autologous peripheral stem cell transplantation ) ; pregnant , lactating woman , woman childbearing age spouse refuse take effective mean contraception contraception ; legal capacity , continue influence medical ethical reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>